GLP-1 Pipeline Update: August 2026

As the GLP-1 pipeline continues to grow, Prime Therapeutics actively monitors this emerging landscape and provides a credible clinical snapshot of what is on the horizon. The below table displays the earliest potential approval dates of the agents listed. Dates are based on manufacturer-published announcements or communications, or are estimated based on study completion dates, and may change as more information becomes available.

	Diabetes + diabetes-related conditions			Obesity or overweight + related conditions							Other
Drug/Dosage form	**T2DM**	**T2DM + CVD**	**Diabetic nephropathy**	**Obesity or overweight**	**Obesity or overweigh + CVD**	**Obesity or overweigh + CLBP**	**Obesity or overweight + HTN**	**Obesity or overweight + OA of knee**	**Obesity or overweight + OSA**	**T1DM ± obesity or overweight**	**MASH**
Amgen											
maridebart cafraglutide/SC				2028							
AstraZeneca											
exenatide (Bydureon BCise)/SC	FDA approved (≥10 years of age)										
exenatide (generic for Byetta)*/SC	FDA approved (≥10 years of age)										
Eli Lilly											
dulaglutide (Trulicity)/SC	FDA approved (≥10 years of age)	FDA approved									
tirzepatide (Mounjaro)/SC	FDA approved (≥10 years of age)	*FDA decision Q3 2026*								2028	
tirzepatide (Zepbound)/SC				FDA approved					FDA approved		
orforglipron (Foundayo)/oral	*FDA decision Q4 2026*			FDA approved			2028		2027		

	Diabetes + diabetes-related conditions			Obesity or overweight + related conditions							Other
Drug/Dosage form	**T2DM**	**T2DM + CVD**	**Diabetic nephropathy**	**Obesity or overweight**	**Obesity or overweigh + CVD**	**Obesity or overweigh + CLBP**	**Obesity or overweight + HTN**	**Obesity or overweight + OA of knee**	**Obesity or overweight + OSA**	**T1DM ± obesity or overweight**	**MASH**
retatrutide/SC	2027			2027	2027	2028		2027	2027		
Novo Nordisk											
liraglutide (Victoza)*/SC	FDA approved (≥10 years of age)	FDA approved									
liraglutide (Saxenda)/SC				FDA approved (≥12 years of age)							
liraglutide + insulin degludec (Xultophy)/SC	FDA approved										
semaglutide (Ozempic) 1.5 mg, 4 mg & 9 mg/oral	FDA approved	FDA approved									
semaglutide (Rybelsus) 3 mg, 7 mg & 14 mg/oral	FDA approved	FDA approved									
semaglutide (Ozempic) 25 mg/oral	*FDA decision Q4 2026*										
semaglutide (Ozempic) 1 mg & 2 mg/SC	FDA approved	FDA approved	FDA approved								
semaglutide (Wegovy) 1.5 mg, 4 mg & 9 mg/oral				FDA approved	FDA approved						
semaglutide (Wegovy) 25 mg/oral				FDA approved	FDA approved						*FDA decision 2026–2027*

	Diabetes + diabetes-related conditions			Obesity or overweight + related conditions							Other
Drug/Dosage form	**T2DM**	**T2DM + CVD**	**Diabetic nephropathy**	**Obesity or overweight**	**Obesity or overweigh + CVD**	**Obesity or overweigh + CLBP**	**Obesity or overweight + HTN**	**Obesity or overweight + OA of knee**	**Obesity or overweight + OSA**	**T1DM ± obesity or overweight**	**MASH**
semaglutide (Wegovy) 1.7 mg & 2.4 mg/SC				FDA approved (≥12 years of age)	FDA approved						FDA approved
semaglutide (Wegovy HD) 7.2 mg/SC				FDA approved							
cagrilintide + semaglutide/SC	2028			*FDA decision December 2026*							
Sanofi											
lixisenatide + insulin glargine (Soliqua)/SC	FDA approved										
Viking											
VK2735/SC				2028							
Zealand, Boehringer Ingelheim											
survodutide/SC				2027	2027						2028 (+obesity)

*Generics available

Glossary

CLBP chronic low back pain
CVD cardiovascular disease
FDA Food and Drug Administration
GLP-1 glucagon-like peptide-1 receptor agonist
HTN hypertension
MASH metabolic dysfunction-associated steatohepatitis
OA osteoarthritis
OSA obstructive sleep apnea
SC subcutaneous
T1DM type 1 diabetes mellitus

Disclaimer